Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

With the stock currently trading at Rs 405.05, Biocon has demonstrated strong financial performance and positive investor sentiment, as reflected by its 52-week high and bullish market outlook.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Nifty rose above 25,100 and Sensex gained 76 points, recovering from earlier losses led by sectoral strength.Stock-Specific ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

On July 9, even when the 90-day pause of Liberation Day ended, Nifty Pharma jumped by over 101 points before correcting.